Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Not yet recruiting 3Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 134Breast Neoplasms 94Colorectal Neoplasms 65Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Lung Neoplasms 45Triple Negative Breast Neoplasms 43Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Small Cell Lung Carcinoma 41Uterine Cervical Neoplasms 40Rectal Neoplasms 37Neoplasms 31Pancreatic Neoplasms 30Recurrence 29Neoplasm Metastasis 29Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Ovarian Neoplasms 23Nasopharyngeal Carcinoma 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Carcinoma, Renal Cell 20Head and Neck Neoplasms 19Endometrial Neoplasms 19Multiple Myeloma 18Biliary Tract Neoplasms 18

Interventions

tislelizumab 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × SCLC, Extensive Stage × Clear all
NCT06793228 2025-01-27

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Henan Cancer Hospital

Phase 2 Not yet recruiting
250 enrolled
Thoracic

SCLC, Extensive Stage

NCT06768307 2025-01-10

Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
60 enrolled
Thoracic

SCLC, Extensive Stage

NCT06620796 2024-10-01

A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting
70 enrolled
Thoracic

SCLC, Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡